Actemra, an injectable treatment for rheumatoid arthritis (RA), has been linked to life-threatening injuries including stroke, heart attack, GI perforation and interstitial lung failure. Additionally, 1,128 pulmonary and cardiovascular deaths in Actemra patients have been reported to the FDA. If you or a loved one has suffered such injuries, or death, as a result of the administration of Actemra, you may be eligible for financial compensation.
What is Actemra?
Approved by the FDA in 2010, Actemra is an injectable immunosuppressive, monoclonal antibody prescription drug, which works to fight the inflammatory conditions in patients with autoimmune diseases, such as rheumatoid arthritis.
Immunosuppressive medications, such as Enbrel, Remicade, and Humira have helped millions of people who suffer from RA; however, they include detailed black-box warnings regarding the risk of infections (tuberculosis, invasive fungal infections, etc.) as well as warnings of lung disease, heart failure, heart attack, stroke, and pancreatitis. Actemra warns of none of these side-effects.
Genentech, the manufacturer of Actemra, and Roche (Genentech’s parent company) have profited more than $1.7 billion in the seven years Actemra has been on the market.
Investigators from STAT found, after analysis of more than 500,000 side-effect reports on several RA prescription drugs, “clear evidence that the risks of heart attacks, strokes, heart failure, and other conditions were as high or higher for Actemra patients than for patients taking some competing drugs.”
Contact the Actemra Litigation Team Today
If you or a loved one have suffered injuries as a result of taking Actemra, contact the Actemra Litigation Team at Kogan & DiSalvo Personal Injury Law now. The call and consultation are free and confidential 800-707-9111.